₹100 tablet to prevent resurgence of cancer developed by Tata Memorial Centre
₹100 tablet to prevent resurgence of cancer developed by Tata Memorial Centre- Cancer, a name synonymous with fear and uncertainty, has plagued humanity for centuries. While advancements in treatment offer hope, the battle against recurrence remains a significant challenge. However, a recent development from the Tata Memorial Centre (TMC) in India has ignited a spark of optimism – a potentially groundbreaking tablet priced at just ₹100 that holds promise for preventing cancer recurrence and reducing treatment side effects.
This innovative tablet, named "R+Cu," is the culmination of nearly a decade of dedicated research by TMC scientists. It contains a unique combination of resveratrol and copper, which, when ingested, generate oxygen radicals within the stomach. These radicals target and destroy circulating chromatin particles (cfChPs) released by dying cancer cells. These cfChPs, if left unchecked, can trigger the transformation of healthy cells into cancerous ones, leading to relapse.
The potential benefits of R+Cu are two-fold. Firstly, it is believed to significantly reduce the debilitating side effects associated with chemotherapy, offering some relief to patients undergoing this challenging treatment. Studies suggest that R+Cu may decrease these side effects by around 50%. Secondly, and perhaps even more importantly, R+Cu exhibits promising results in preventing cancer recurrence. While not a complete cure, it is reported to be around 30% effective in lowering the risk of cancer returning.
While the initial research on R+Cu is encouraging, it's crucial to remember that it is still undergoing clinical trials. As with any new drug, obtaining regulatory approval from the Food Safety and Standards Authority of India (FSSAI) is essential before it becomes widely available. This process is expected to be completed by June-July 2024, paving the way for potential market release.
The affordability of R+Cu is another noteworthy aspect. Compared to the often exorbitant costs of cancer treatment, which can range from lakhs to crores, this ₹100 tablet presents a beacon of hope, particularly for individuals facing financial constraints. Its accessibility has the potential to revolutionize cancer care, making preventive measures more readily available to a wider population.
The development of R+Cu by the Tata Memorial Centre represents a significant step forward in the fight against cancer. While further research and development are necessary, this innovation offers a glimmer of hope for millions battling this formidable disease. It serves as a testament to the unwavering dedication of scientists and researchers who strive to make a tangible difference in the lives of those affected by cancer.
It's important to consult with a qualified medical professional for personalized advice and treatment options. R+Cu, while promising, should not be considered a substitute for established cancer treatment protocols. However, its potential to alleviate side effects and decrease recurrence rates presents a compelling reason for continued research and development.